35 results about "Methimazole" patented technology

Methods of ameliorating episodes of accute or chronic colitis are provided by using methimazole derivatives and tautomeric cyclic thiones in combination with another pharmaceutical compound.

Treatment of autoimmune and / or inflammatory diseases associated with overexpression of Toll-like receptor 3 (TLR3) as well as Toll-like receptor 4 (TLR4) and / or TLR3 / TLR4 signaling in nonimmune cells, monocytes, macrophages, and / or dendritic cells in association with related pathologies. The use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune and inflammatory diseases associated with TLR3 as well as TLR4 and / or TLR3 / TLR4 cellular signaling in association with related pathologies is disclosed. Methods of treating a subject having a disease or condition associated with abnormal TLR-3 as well as TLR-4 and / or TLR3 / TLR4 cellular signaling in association with related pathologies are also disclosed. The present disclosure also relates to the treatment of autoimmune-inflammatory pathologies and chemokine and cytokine-mediated diseases associated with TLR overexpression and signaling. The disclosure also relates to pharmaceutical formulations capable of inhibiting the IRF-3 / Type 1 IFN / STAT / ISRE / IRF-1 pathway associated with Toll-like receptor overexpression or signaling.

The present invention discloses for the first time the pharmaceutical application of rapamycin in the treatment of refractory GD. The combined treatment of rapamycin + methimazole can improve the TSH and TRAb levels of patients with refractory GD; and, the Treg / CD4+ in patients The ratio of T increased, the ratio of Th17 / CD4+T and the ratio of Th17 / Treg decreased; at the same time, the plasma levels of Th17 and Treg cell-related cytokines, including IL-17A, IL-6 and TGF-β1, were significantly improved. The dose of rapamycin for refractory GD is 0.5 mg / day, and the trough concentration of the drug is 2-4 ng / mL. There were no obvious adverse reactions in the combined treatment group of rapamycin + methimazole. Therefore, the experimental results of the present invention fully support the new application of rapamycin in the treatment of refractory GD, and the combined treatment of rapamycin + methimazole is a new direction for the treatment of refractory GD worth exploring.

The invention relates to a pharmaceutical composition for treating hyperthyroidism, a preparation containing the same, a preparation method and application thereof. The pharmaceutical composition contains the following active components in parts by weight: 6-12 parts of methimazole, 2800-5200 parts of kelp, 2800-5200 parts of thunberg fritillary bulb, 3500-6500 parts of coix seeds, 3500-6500 parts of cortex eucommiae, 3500-6500 parts of dogwood, 2800-5200 parts of hemlock parsley, 3500-6500 parts of airpotato yam, 4900-9100 parts of angelica sinensis and 4200-7800 parts of fermented soybeans. The pharmaceutical composition for treating hyperthyroidism provided by the invention adopts a method with combination of Chinese traditional and western medicine, gives full play to the synergistic effect of Chinese traditional and western medicine, reduces adverse reaction of the pharmaceutical composition, enhances the curative effect, shortens the course of treatment and increases tolerance of patients.

The invention belongs to the technical field of medicine and health and relates to a preparation method of a nanogold-containing antibacterial agent. The preparation method comprises the following steps that A, egg white is centrifuged, liquid supernatant is taken, and a reactant A is obtained; B, under the temperature condition of 20-30 DEG C, distilled water is added in the reactant A obtained in the step A to dilute till the mass fraction is 1-5%, a sodium hydroxide solution is used for adjusting the pH to be 9-11, uniform mixing is conducted, and a mixed solution is obtained; C, under thetemperature condition of 80-100 DEG C, a chloroauric acid solution is added in the mixed solution obtained in the step B to react for 20-30 min, and then a nanogold-containing solution is obtained; and D, under the temperature condition of 80-100 DEG C, a methimazole solution is added in the nanogold-containing solution obtained in the step C, stirring and mixing are conducted, and after reaction,the nanogold-containing antibacterial agent is obtained. The nanogold-containing antibacterial agent has the excellent antibacterial property and biocompatibility, the safety and reliability are achieved, and the preparation method of the nanogold-containing antibacterial agent is simple.

The invention discloses the application of HLA‑DRB1*04:03 allele in evaluating the risk of drug eruption caused by methimazole. The present invention claims the application of the material used for detecting the HLA‑DRB1*04:03 allele in the preparation of the kit. The present invention also protects a kit comprising materials for detecting HLA‑DRB1*04:03 alleles. Functions of the kit: (a) evaluate the risk of the subject’s drug eruption caused by methimazole; (b) evaluate the risk of the subject’s drug eruption caused by methimazole; carry HLA‑DRB1*04:03, etc. Subjects with alleles have a higher risk of drug eruption after taking methimazole than subjects without HLA‑DRB1*04:03 alleles; (c) evaluate whether subjects are suitable for taking methimazole; ( d) Evaluate whether the subject is suitable for taking methimazole; subjects carrying the HLA‑DRB1*04:03 allele are not suitable for taking methimazole.

The invention discloses a methimazole synthesizing and purifying method, and belongs to the field of medicine synthesis. The method comprises the following steps: carrying out a condensation reaction on methylaminoacetaldehyde polyethylene glycol and ammonium thiocyanate which are used as raw materials in the presence of an acid catalyst and a phase transfer catalyst; and adding saturated salt water after the reaction is completed, uniformly mixing the obtained reaction product and the saturated salt water, adding an organic solvent to carry out extraction, drying and concentrating the obtained organic layer to obtain crude methimazole, heating and dissolving the crude product in a solvent, adding active carbon to decolorize the obtained solution, filtering the solution, and drying the filtered solution to obtain purified methimazole. The method is a preparation method simple to operate and suitable for industrial production.

The invention provides a nano-gold colorimetric method based on the principle of anti-agglomeration and a method for measuring the content of silver ions in water samples. The method comprises the following steps: take 200 μL of the nano-gold solution prepared by sodium citrate reduction, add 200 μL of a certain concentration of methimazole solution, then add 400 μL of BR buffer solution, shake well and incubate for 5 minutes, perform ultraviolet-visible spectrum scanning, and measure the concentration of the solution at 520 The absorbance at nm and 660 nm, the ratio of the absorbance of the solution A 520 / A 660 as A 0 ; Then take 200 μL of methimazole at a certain concentration and 200 μL of silver ion solution at a certain concentration, add 200 μL of BR buffer solution, shake well and incubate for 10 minutes, then add 200 μL nano-gold solution, shake well and incubate for 5 minutes, and perform UV-visible spectrum scanning. Measure the absorbance of the solution at 520 nm and 660 nm, and the absorbance ratio of the solution A 520 / A 660 as A 1 , after adding silver ions, the change of absorbance ratio has a linear relationship with the concentration of silver ions, so the content of silver ions in water samples can be quickly, sensitively and accurately determined. The invention has good selectivity, high sensitivity and wide detection range, only needs ultraviolet spectrophotometer measurement, does not need large-scale instruments, has low operation requirements, and has wide application prospects.

The invention discloses a weeding composition containing imazameth and clethodim. The weeding composition comprises active components, that is, imazameth and clethodim, and the balance of pesticide additives, wherein the mass part ratio of imazameth to clethodim is (1:10) to (10:1); the mass sum of imazameth and clethodim accounts for 1-80% of the weeding composition percentage by mass. The weeding composition disclosed by the invention has a remarkable synergism function, is applicable to prevention and treatment on annual weeds in peanut fields, and is relatively applicable to a post-emergence spraying method.

The invention relates to a preparation process of 7-ATCA. The preparation process comprises the following steps: (1) mixing dimethyl carbonate with a boron trifluoride dimethyl carbonate complex, adding 7-ACA and methimazole tetrazolylazo, and stirring to react at 15-20 DEG C until the residue of 7-ACA is less than or equal to 1% by virtue of liquid detection; (2) cooling reaction liquid to 5-15 DEG C, and adding purified water with the temperature of 5-15 DEG C for hydrolysis; (3) after adding dichloromethane for once extraction, adding dichloromethane into a water layer for secondary extraction; (4) dropwise adding weak base into the water layer at 0-10 DEG C until the pH is 3.4-3.6, and stirring to grow crystals at 0-10 DEG C for 2h, wherein the temperature in the dropwise adding process does not exceed 10 DEG C; and (5) carrying out centrifugation, sequentially washing with purified water and acetone, and drying, so as to obtain 7-ATCA. By virtue of the preparation process, a 7-ATCA product with good crystal form and particle size can be obtained and is a white crystal, the purity can reach 99.5% or above, and the mass yield can reach 115% or above.

The invention relates to methimazole microemulsion, methimazole microemulsion-based gel and a preparation method and application of the methimazole microemulsion. The methimazole microemulsion comprises methimazole, oil, surfactant, cosurfactant, water and transdermal Enhancer according to a weight ratio of 1:(1.40-4.25):(5.13-15.45):(5.13-15.45):(1.40-8.32):(0.26:1.26). The methimazole microemulsion-based gel is prepared by adding gel matrix into the methimazole microemulsion, allowing swelling and performing uniform mixing. The methimazole microemulsion and the methimazole microemulsion-based gel are directly applicable to affected parts, are also applicable to the preparation of hyperthyroidism pharmaceuticals such as patches or plasters, and have the advantages such as good solubility, high penetration capacity, long acting time, evident improvement in therapeutic effect, fewer times of administration, and convenience of administration.